Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1166-1169

  Unizony, Sebastian ^a   Villarreal, Miguel ^b   Miloslavsky, Eli M ^a   Lu, Na ^a   Merkel, Peter A ^c   Spiera, Robert ^d   Seo, Philip ^e   Langford, Carol A ^f   Hoffman, Gary S ^f   Kallenberg, C G M ^g   St Clair, E William ^h   Ikle, David ^b   Tchao, Nadia K ⁱ   Ding, Linna ^j   Brunetta, Paul ^k   Choi, Hyon K ^a   Monach, Paul A ^l   Fervenza, Fernando ^m   Stone, John H ^a   Specks, Ulrich ^m  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Rho   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Immune Tolerance Network   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k GENENTECH INC   (United States)

^l BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ENZYME ANTIBODY; MYELOPEROXIDASE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROTEINASE 3 ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MYELOBLASTIN; PEROXIDASE;

ADULT; ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SYNDROME DELINEATION; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BLOOD; COMBINATION DRUG THERAPY; GRANULOMATOSIS WITH POLYANGIITIS; IMMUNOLOGY; MICROSCOPIC POLYANGIITIS; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AZATHIOPRINE; BIOMARKERS; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; MYELOBLASTIN; PEROXIDASE; PROGNOSIS; REMISSION INDUCTION; RITUXIMAB; TREATMENT OUTCOME;

EID: 84954288948     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208073     Document Type: Article

References (20)

1. Jones R B, Tervaert J W, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20. .
2. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
3. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771-80.
4. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
5. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:417-27.
6. Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCAassociated vasculitis with renal involvement. J Am Soc Nephrol 2015;26:976-85.
7. Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 2015;74:1178-82.
8. Specks U, Seyfert-Margolis V, Merkel PA, et al. Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) trial. Open Arthritis J 2011;4:1-18.
9. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
10. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912-20.
11. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
12. Seo P, Min YI, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78.
13. McGregor JG, Negrete-Lopez R, Poulton CJ, et al. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant 2015;30(Suppl 1):i171-81.
14. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43.
15. Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-8.
16. Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-62.
17. Li ZY, Chang DY, Zhao MH, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol 2014;66:1920-6.
18. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421-30.
19. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007;120:643.e9-14.
20. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41:1521-37.